Can-Fite BioPharma Ltd. (CANF)
|52 Week Range||1.52-8.4|
|1y Target Est||-|
|DCF Unlevered||CANF DCF ->|
|DCF Levered||CANF LDCF ->|
|Debt / Equity||0.97%||Neutral|
Upgrades & Downgrades
Latest CANF news
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
22 November 2023
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.
3 Top Penny Stocks To Watch Before Next Week
21 November 2023
As retail investors seek explosive returns, penny stocks remain enticing potential opportunities capable of massive short-term gains. However, the considerable risks of these cheap equities also highl...
New Strong Buy Stocks for October 27th
27 October 2023
MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
7 July 2023
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncolog...
Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer
14 June 2023
Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion studies for namodenoson to treat pancreatic carcino...
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
10 May 2023
Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
2 May 2023
Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction.
All You Need to Know About CanFite Biopharma Ltd (CANF) Rating Upgrade to Buy
26 July 2022
CanFite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial
29 June 2022
Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show that ...